← Back to Analyst Consensus 
STOK Buy
Stoke Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 20
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 2, 2026 (7 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 4, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Aug 4, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Aug 4, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Aug 4, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Jul 13, 2026 | Goldman Sachs | initiate | — → Buy | — | 54% |
| May 11, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Mar 20, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Mar 19, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Mar 18, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Mar 18, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Mar 17, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Mar 17, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Feb 24, 2026 | Wolfe Research | initiate | — → Outperform | $40 | 53% |
| Jan 12, 2026 | Wedbush | maintain | Outperform → Outperform | $36 | 58% |
| Jan 5, 2026 | Chardan Capital | maintain | Buy → Buy | $35 | 47% |
| Jan 5, 2026 | Canaccord Genuity | maintain | Buy → Buy | $36 | 48% |
| Dec 15, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $50 | 44% |
| Nov 5, 2025 | Canaccord Genuity | maintain | Buy → Buy | $28 | 48% |
| Nov 5, 2025 | Wedbush | maintain | Outperform → Outperform | $32 | 58% |
| Nov 5, 2025 | BTIG | reiterate | Buy → Buy | $39 | 52% |
| Nov 3, 2025 | JP Morgan | maintain | Neutral → Neutral | $25 | 54% |
| Oct 13, 2025 | BTIG | maintain | Buy → Buy | $39 | 52% |
| Oct 10, 2025 | Needham | maintain | Buy → Buy | $35 | 50% |
| Aug 13, 2025 | Chardan Capital | maintain | Buy → Buy | $24 | 47% |
| Aug 13, 2025 | Wedbush | maintain | Outperform → Outperform | $22 | 58% |
| Jul 18, 2025 | Jefferies | initiate | — → Buy | $30 | 52% |
| Jul 1, 2025 | Needham | reiterate | Buy → Buy | $22 | 50% |
| May 14, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $35 | 44% |
| Apr 9, 2025 | Needham | reiterate | Buy → Buy | $22 | 50% |
| Mar 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $47 | 44% |
| Mar 19, 2025 | Chardan Capital | maintain | Buy → Buy | $24 | 47% |
| Mar 18, 2025 | Needham | reiterate | Buy → Buy | $22 | 50% |
| Feb 19, 2025 | Chardan Capital | maintain | Buy → Buy | $24 | 47% |
| Feb 18, 2025 | Needham | reiterate | Buy → Buy | $22 | 50% |
| Feb 18, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $47 | 44% |
| Jan 8, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $35 | 44% |
| Jan 8, 2025 | Needham | maintain | Buy → Buy | $22 | 50% |
| Dec 20, 2024 | Chardan Capital | initiate | — → Buy | $24 | 47% |
| Dec 10, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $0 | 50% |
| Nov 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
| Nov 6, 2024 | Needham | reiterate | Buy → Buy | $22 | 50% |
| Sep 11, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
| Aug 8, 2024 | Needham | reiterate | Buy → Buy | $22 | 50% |
| Jul 11, 2024 | Wedbush | reiterate | Outperform → Outperform | $17 | 58% |
| Jun 28, 2024 | Needham | reiterate | Buy → Buy | $22 | 50% |
| May 7, 2024 | Canaccord Genuity | maintain | Buy → Buy | $20 | 48% |
| May 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $35 | 44% |
| May 6, 2024 | Needham | reiterate | Buy → Buy | $22 | 50% |
| Apr 11, 2024 | Needham | reiterate | Buy → Buy | $22 | 50% |
| Apr 4, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
Price Target Trend
May 5, 2026 Oct 26, 2026
EPS Estimates
0q —
+1q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days